XBI leads major biotech ETFs in fund flows

All three major biotech ETFs saw inflows in July, with the XBI maintaining its lead for the year as the largest target for incoming capital.

The month of July marked the first time this year the S&P Biotech ETF (XBI), iShares Biotechnology ETF (IBB) and ARK Genomic Revolution ETF (ARKG) each saw inflows in a calendar month. But the XBI is far outpacing the other ETFs year-to-date, pulling in over $2.3 billion, while the IBB and ARKG have seen cumulative outflows of $57.2 million and $262 million over the same period, respectively...